Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aprea Presents Preclinical Data at AACR

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Strong synergistic effect with APR-246 and cisplatin.

Aprea AB has presented preclinical data at the American Association for Cancer Research (AACR) meeting in Washington, DC, USA.

The results from these studies show that Aprea’s lead candidate APR-246, a compound that reactivates mutant p53, acts synergistically with platinum compounds.

Aprea, which is part of the Karolinska Development portfolio, is now preparing a Phase II study with APR-246 in platinum resistant ovarian cancer.

The title of Aprea’s poster presentation at AACR was “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients”.

In the studies, the anticancer effect of APR-246 alone, and in combination with platinum compounds, on ovarian cancer cells were investigated.

The results show that APR-246 acts synergistically with platinum compounds and reverses the cisplatin-sensitivity to cisplatin-resistant p53 mutant ovarian cancer cells.

Aberrations in p53 are common in many cancer forms and are associated with increased resistance to standard chemotherapy resulting in a poor prognosis for the patient. About 60% of ovarian cancer patients have p53 mutations.

Mikael von Euler, CMO of Aprea, commented; “We are very pleased with this comprehensive set of preclinical data supporting our planned Phase II study in platinum-resistant Epithelial Ovarian Cancer (EOC) patients who are candidates for further platinum-based chemotherapy. APR-246 has the potential to be an important new treatment for these patients with high unmet medical need”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aprea Granted European Orphan Drug Designation for APR-246 in Ovarian Cancer
Company is currently conducting a Phase Ib/II trial of APR-246.
Saturday, January 24, 2015
Aprea Strengthens its Board
Company elects Bernd R. Seizinger as new member of the board.
Tuesday, January 21, 2014
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
A New Way Out for Stem Cells
Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
Designing Potential AIDS Vaccine Candidates
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anticancer Drug Stops Ebola Virus Molecule in its Tracks
A team of scientists from the University of Oxford have successfully mapped the structure of the Ebola virus molecule that drives the attack strategy and leads to fatal infections in humans.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!